Cardiff Lexington Corporation (Stock Symbol: CDIX) is a targeted healthcare holding company dedicated to acquiring and building middle-market niche health care clinics, primarily in Orthopedics, Spine Care, and Pain Management. The CDIX partnership-driven culture emphasizes service excellence, teamwork, accountability, and performance.
All current CDIX revenue is derived from Nova Ortho and Spine, LLC, which operates a network of regional specialty and ancillary orthopedic care centers across Florida and Georgia. These facilities provide traumatic injury patients with comprehensive diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultations.
Addition of Southeastern Surgery Center in Tallahassee, Florida to Nova Ortho and Spine Network
On June 29th CDIX announced that its Nova Ortho and Spine subsidiary has added Southeastern Surgery Center in Tallahassee, Florida to its growing network of surgical facilities, enhancing access to advanced orthopedic and spine care for patients in this region.
Southeastern Surgery Center has earned a strong reputation over many years of operation, recognized for its commitment to exceptional patient care, outstanding patient satisfaction, and stringent patient safety standards. CDIX Nova Ortho and Spine has begun performing minimally invasive pain management and spine procedures at Southeastern Surgery Center. These advanced procedures offer patients shorter recovery times, and less postoperative discomfort. The practice plans to expand its surgical offerings at the facility to include open procedures in the near future.
Alex Cunningham, Chief Executive Officer of CDIX, commented, “The addition of Southeastern Surgery Center as the 12th surgical center in the Nova Ortho and Spine network aligns perfectly with our long-term strategy to provide best in class patient-centered care to underserved populations. As the capital city of Florida, Tallahassee represents a strategic metropolitan location with high patient volume and visibility. This is a natural next step in our continued expansion in the southeast US and mid-Atlantic.”
Medical Office in Stuart, Florida to Serve the Growing Treasure Coast Community
On May 20th CDIX announced that Nova Ortho and Spine, a wholly owned subsidiary, has opened a new location in Stuart, Florida. This new location further strengthens the CDIX Nova Ortho and Spine’s expanding regional network of healthcare facilities throughout Florida and supports the organization’s broader strategy of increasing accessibility to specialized orthopedic and spine services in underserved and high-growth markets.
Strategically positioned along the Federal Highway corridor with convenient access to major regional transportation routes, the newly developed 2,975-square-foot clinic expands Nova the CDIX Ortho and Spine’s footprint along Florida’s Treasure Coast and will provide comprehensive orthopedic, spine, and musculoskeletal care services to patients throughout Stuart, Palm City, Jensen Beach, Port St. Lucie, and surrounding Martin and St. Lucie County communities. The facility is designed to provide efficient patient flow, modern clinical infrastructure, and a patient-centered care environment focused on orthopedic evaluation, spine care, diagnostics, and non-surgical treatment options.
According to recent regional demographic estimates, the combined population of Martin and St. Lucie Counties now exceeds 650,000 residents, with continued growth projected over the coming decade. The Treasure Coast region also maintains one of Florida’s highest concentrations of residents aged 55 and older – a demographic frequently requiring orthopedic, spine, pain management, and mobility-related healthcare services.
First Quarter 2026 Financial Results
On May 19th CDIX announced financial results for the first quarter ended March 31, 2026.
Alex Cunningham, Chief Executive Officer of CDIX, commented, “We continue to strengthen and expand our network of Nova Ortho and Spine locations to support growing patient demand with a focus on more high value procedures, and we remain confident in our ability to build a scalable platform through organic growth and acquisitions that deliver exceptional outcomes for patients. Furthermore, our recent upgrade to the OTCQX market represents an important step in increasing our visibility and credibility among institutional investors as we execute our strategic initiatives to enhance our access to working capital and drive sustainable, long-term growth and shareholder value.”
CDIX Total Revenue was $2.2 million compared with $2.9 million in the first quarter of 2025. The decrease in revenue is mainly attributable to a decrease in surgical procedures in the first quarter of 2026 compared to the first quarter of 2025.
Gross profit was $1.3 million, or 59.3% of total revenue, compared with $1.8 million, or 63.1% of total revenue in the first quarter of 2025.
CDIX Cash totaled $684,000 as of March 31, 2026.
CDIX Total Assets increased 4.1% to $30.3 million as of March 31, 2026.
Upgrade to OTCQX Best Market
On April 9th CDIX announced that its common stock has been approved to trade on the OTCQX® Best Market, the highest-level market of the OTC Markets.
The OTCQX Best Market is designed for established, investor-focused companies and requires high financial standards, strong corporate governance, and compliance with applicable securities laws.
Upgrading to OTCQX from the OTCQB® Venture Market reflects the CDIX continued commitment to enhanced transparency and maintaining the highest governance and financial reporting standards available to companies trading on the OTC Markets.
CDIX has demonstrated consistent financial growth and operating performance driven by its focused healthcare platform strategy.
CDIX performance reflects a high-margin operating model within the orthopedic and spine care sector and underscores management’s focus on scalable, capital-efficient growth.
Execution of Proven Three-Pillar Growth Strategy
CDIX continues to execute on its differentiated three-pillar strategy, designed to drive sustainable revenue growth, expand margins, and enhance long-term shareholder value:
Core Cash Flow Platform – Acquisition and optimization of physician orthopedic and related practices to generate consistent, recurring revenue streams
Asset Acquisition – Strategic acquisition of ambulatory surgery centers (ASCs), MRI Clinics, and clinic real estate to enhance operating leverage and asset-backed value
Finance Strategy – Retention and management of personal injury-related accounts receivable to maximize long-term cash yield versus discounted third-party sales
This integrated approach has enabled CDIX to establish a high-margin operating model within a fragmented and supply-constrained healthcare segment, positioning it for disciplined expansion through both organic growth and targeted acquisitions in one of the most resilient segments of U.S. Healthcare that offers an exceptional balance of downside protection, sustainable profitability, and scalable growth.
The CDIX operating platform, anchored by its subsidiary Nova Ortho and Spine, continues to experience strong demand across its markets and currently operates below full capacity primarily due to working capital constraints rather than clinical or operational limitations.
CDIX is actively pursuing strategic initiatives to:
Expand working capital to support increased patient volume and procedural throughput
Reduce reliance on higher-cost financing structures
Accelerate accounts receivable conversion cycles
Enhance overall EBITDA generation and cash flow visibility
CDIX has demonstrated and proven the ability to deploy capital at a very high rate of return. Management believes that improving access to cost-efficient growth capital will allow CDIX to materially increase utilization rates and unlock embedded operating leverage across its platform.
The OTCQX upgrade represents an important step in the CDIX broader capital markets strategy, which includes pursuing a future uplisting to a national securities exchange, such as the NYSE American or Nasdaq Capital Market, subject to meeting applicable listing requirements.
For more information on CDIX visit: https://cardifflexington.com/
Email: [email protected]
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Media ContactCompany Name: Cardiff Lexington Corporation (CDIX)Contact Person: Alex Cunningham, CEOEmail: Send EmailPhone: (800) 628-2100Address:3753 Howard Hughes Parkway Suite 200 City: Las VegasState: NV 89169Country: United StatesWebsite: https://cardifflexington.com/
